Stockscreener 앱 받기
2.49
7.33%
0.17
전일 마감가:
$2.32
열려 있는:
$2.32
하루 거래량:
84,665
Relative Volume:
0.45
시가총액:
$116.21M
수익:
-
순이익/손실:
$-82.60M
주가수익비율:
-1.2087
EPS:
-2.06
순현금흐름:
$-48.61M
1주 성능:
+2.89%
1개월 성능:
+64.90%
6개월 성능:
-21.94%
1년 성능:
-29.66%
1일 변동 폭
$2.32
$2.59
1주일 범위
$2.26
$2.65
52주 변동 폭
$1.312
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
명칭
Vigil Neuroscience Inc
전화
857-254-4445
주소
100 FORGE ROAD, WATERTOWN
VIGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
2.49 | 112.95M | 0 | -82.60M | -48.61M | -2.06 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-04 | 개시 | William Blair | Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2022-09-16 | 개시 | Wedbush | Outperform |
| 2022-08-29 | 개시 | H.C. Wainwright | Buy |
| 2022-02-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 개시 | Jefferies | Buy |
| 2022-02-01 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-01 | 개시 | Stifel | Buy |
모두보기
Vigil Neuroscience Inc 주식(VIGL)의 최신 뉴스
Barclays PLC Purchases 19,436 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Q2 EPS Estimate for Vigil Neuroscience Increased by Analyst - Defense World
HC Wainwright Expects Higher Earnings for Vigil Neuroscience - Defense World
HC Wainwright Has Optimistic Outlook of VIGL FY2029 Earnings - Defense World
Wedbush Raises Earnings Estimates for Vigil Neuroscience - Defense World
Vigil Neuroscience Advances Clinical Trials and Financial Stability - TipRanks
Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year - TipRanks
Vigil Neuroscience, Inc. SEC 10-Q Report - TradingView
Vigil Neuroscience Reports Q1 2025 Financial Results and Updates on Clinical Trials for Iluzanebart and VG-3927 - Nasdaq
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates - GlobeNewswire
Vigil Neuroscience (NASDAQ:VIGL) Given “Outperform” Rating at Wedbush - Defense World
Form 8-KCurrent report - ADVFN
Vigil Neuroscience (NASDAQ:VIGL) Upgraded at William Blair - Defense World
Vigil Neuroscience stock hits 52-week low at $1.43 - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $1.43 By Investing.com - Investing.com South Africa
Vigil Neuroscience Presents Data on its Small Molecule - GlobeNewswire
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials By Investing.com - Investing.com South Africa
Vigil presents data on oral small molecule program including VG-3927 - TipRanks
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials - Investing.com
Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies - Stock Titan
Vigil Neuroscience Reports 2024 Results and Clinical Progress - TipRanks
Vigil Neuroscience Files Secondary Stock Shelf - MarketScreener
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Decline in Short Interest - Defense World
Vigil Neuroscience (VIGL) to Release Earnings on Tuesday - Defense World
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 By Investing.com - Investing.com Canada
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 - Investing.com India
FY2029 Earnings Forecast for VIGL Issued By Wedbush - Defense World
Q1 Earnings Estimate for VIGL Issued By William Blair - Defense World
HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating - TipRanks
Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating - Marketscreener.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com Australia
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com India
Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com
Vigil Neuroscience, Inc. SEC 10-K Report - TradingView
Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq
Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq
Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire
Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan
SPY ETF News, 3/13/2025 - The Globe and Mail
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire
Vigil Neuroscience Inc (VIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Vigil Neuroscience Inc 주식 (VIGL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
1.54%
7.58%
자본화:
|
볼륨(24시간):